시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 포스포이노시티드 3 키나아제(PI3K) 억제제 시장 보고서(2025년)
Phosphoinositide 3-Kinase (PI3K) Inhibitors Global Market Report 2025
상품코드 : 1751073
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,686,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,665,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,644,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

포스포이노시티드 3 키나아제(PI3K) 억제제 시장 규모는 향후 수 년간 급성장할 것으로 예측됩니다. 예측되는 성장은 병용요법에 대한 수요 증가, 안전성 프로파일이 개선된 차세대 PI3K 억제제의 출현, 암 연구개발에 대한 투자 증가, 종양학 이외의 적응확대, 환자선택 바이오마커의 채용 확대 등, 여러 요인에 기인하고 있습니다. 이중 및 범이소형 PI3K 억제제로의 전환, 정맥 주사 옵션보다 경구용 제제에 대한 선호도 증가, 내성 메커니즘의 극복에 대한 주력의 향상, 신약에서의 인공지능의 통합의 진전, 면역요법과의 병용에 있어서의 PI3K 억제제의 역할의 확대 등을 들 수 있습니다.

암과 자가면역질환의 유병률 증가는 향후 몇 년간의 포스포이노시티드 3 키나아제(PI3K) 억제제 시장의 성장을 크게 견인할 것으로 예측됩니다. 모두 증가 추세에 있습니다. 이것은 유전적 소인, 축적된 유전자 돌연변이 및 장기간에 걸쳐 면역계의 조절 장애로 인한 것이 큽니다. 이를 통해 이러한 질병의 발생률을 높이는 데 필수적입니다. 이 억제제는 치료 효과와 환자 결과를 개선하는 정밀의료 접근법을 제공합니다. 국립암연구소는 미국 내 암 생존자 수가 2022년 1,810만명에서 2032년에는 2,250만명으로 증가할 것으로 예측했습니다.

PI3K 억제제 시장의 주요 기업은 PI3K 신호전달 이상과 관련된 질환에 대처하기 위해 PI3K 델타 억제제 치료를 포함한 표적 치료의 개발에서 크게 전진하고 있습니다. PI3K 델타 억제제는 면역 세포 신호 전달에 중요한 역할을 하는 PI3K 델타 효소를 표적으로 합니다. 이 효소를 억제함으로써, 이러한 치료제는 염증, 자가면역 반응, 특정 혈액암을 억제할 수 있습니다. 타증후군(APDS)에 대한 최초의 치료제인 조엔야(레니오리시브)를 승인했습니다. 이번 승인은 PIK3CD 또는 PIK3R1 유전자의 유전자 돌연변이로 인한 면역 기능 장애를 해결하기 위한 정밀 치료 접근법을 제공하는 개인 맞춤 의학 분야에서 중요한 이정표가 되었습니다. Joenja의 승인은 PI3K 억제제가 암 영역뿐만 아니라 희귀한 면역 질환의 치료에도 사용되고 있음을 나타내는 것으로, 시장에서 보다 표적을 좁힌 맞춤형 치료로의 전환이 진행되고 있음을 강조하는 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Phosphoinositide 3-Kinase (PI3K) inhibitors are a class of drugs that target the PI3K enzyme, which plays a crucial role in regulating cell growth, survival, and metabolism. These inhibitors help control abnormal cell division and tumor growth, making them effective in treating various cancers, including breast cancer, leukemia, and lymphoma. PI3K inhibitors work by blocking signaling pathways that promote the survival and proliferation of cancer cells, ultimately slowing down or halting tumor progression.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of PI3K inhibitors include isoform-selective inhibitors, pan-PI3K inhibitors, dual PI3K or mechanistic target of rapamycin (mTOR) inhibitors, and novel targeted inhibitors. Isoform-selective inhibitors are specialized compounds that selectively target and inhibit specific isoforms of an enzyme or protein, reducing off-target effects and improving therapeutic precision. These inhibitors are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. They are primarily used in cancer treatment, metabolic disorders, autoimmune diseases, and neurological disorders, with end-users including hospitals, research institutes, pharmaceutical companies, and contract research organizations (CROs).

The phosphoinositide 3-kinase (PI3K) inhibitors market research report is one of a series of new reports from The Business Research Company that provides phosphoinositide 3-kinase (PI3K) inhibitors market statistics, including phosphoinositide 3-kinase (PI3K) inhibitors industry global market size, regional shares, competitors with a phosphoinositide 3-kinase (PI3K) inhibitors market share, detailed phosphoinositide 3-kinase (PI3K) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the phosphoinositide 3-kinase (PI3K) inhibitors industry. This phosphoinositide 3-kinase (PI3K) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The phosphoinositide 3-kinase (PI3K) inhibitors market size has grown rapidly in recent years. It will grow from $1.38 billion in 2024 to $1.57 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of cancer, growing research on targeted therapies, regulatory approvals for first-generation PI3K inhibitors, rising healthcare expenditure, and the expansion of clinical trials for hematologic malignancies.

The phosphoinositide 3-kinase (PI3K) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth projected for the forecast period can be attributed to several factors, including the increasing demand for combination therapies, the emergence of next-generation PI3K inhibitors with improved safety profiles, rising investment in cancer research and development, the expansion of indications beyond oncology, and the growing adoption of biomarkers for patient selection. Key trends during this period include a shift toward dual and pan-isoform PI3K inhibitors, a growing preference for oral formulations over intravenous options, a greater focus on overcoming resistance mechanisms, the increasing integration of artificial intelligence in drug discovery, and the expanding role of PI3K inhibitors in immunotherapy combinations.

The increasing prevalence of cancer and autoimmune diseases is expected to significantly drive the growth of the phosphoinositide 3-kinase (PI3K) inhibitors market in the coming years. Cancer, which involves uncontrolled cell growth, and autoimmune diseases, where the immune system mistakenly attacks the body's own tissues, are both on the rise. This is largely due to genetic predispositions, accumulated genetic mutations, and immune system dysregulation over time. PI3K inhibitors are essential in addressing the rising incidence of these diseases by targeting abnormal PI3K signaling pathways, which are implicated in tumor progression and immune system dysfunction. These inhibitors offer precision medicine approaches that improve treatment efficacy and patient outcomes. For example, the National Cancer Institute projected that the number of cancer survivors in the U.S. would rise from 18.1 million in 2022 to 22.5 million by 2032. This indicates a growing demand for treatments, including PI3K inhibitors, to manage cancer and autoimmune diseases, driving the market forward.

Leading companies in the PI3K inhibitors market are making significant strides in developing targeted therapies, including PI3K delta inhibitor treatments, to address diseases linked to dysregulated PI3K signaling. PI3K delta inhibitors specifically target the PI3K delta enzyme, which plays a crucial role in immune cell signaling. By inhibiting this enzyme, these therapies can help reduce inflammation, autoimmune responses, and certain blood cancers. For instance, in March 2023, the U.S. Food and Drug Administration (FDA) approved Joenja (leniolisib), the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older. This approval marked a significant milestone in personalized medicine, offering a precision treatment approach to address immune dysfunction caused by genetic mutations in the PIK3CD or PIK3R1 genes. The approval of Joenja demonstrates how PI3K inhibitors are being used not just in oncology but in treating rare immunological disorders, underscoring the shift towards more targeted, individualized therapies in the market.

In October 2024, OnKure Therapeutics, a U.S.-based biopharmaceutical company, merged with Reneo Pharmaceuticals to create a combined entity focused on advancing mutant-selective PI3Ka inhibitors for cancer treatment. This merger, which involved a substantial financial commitment, aims to accelerate the development of precision medicines that specifically target mutant PI3Ka enzymes implicated in various cancers. PI3Ka inhibitors, which selectively target mutant forms of the PI3K alpha enzyme, are being explored as a potential treatment for cancers that have developed resistance to traditional therapies. The merger strengthens both companies' positions in oncology and accelerates the clinical development of novel therapies, potentially transforming cancer treatment paradigms and expanding the PI3K inhibitors market.

Major players in the phosphoinositide 3-kinase (pi3k) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences, Boehringer Ingelheim, Genentech Inc., Incyte Corporation, Exelixis, Kura Oncology, TG Therapeutics Inc., Verastem Oncology.

North America was the largest region in the phosphoinositide 3-kinase (PI3K) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in phosphoinositide 3-kinase (PI3K) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the phosphoinositide 3-kinase (PI3K) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The phosphoinositide 3-kinase (PI3K) inhibitors market consists of sales of oral formulations, intravenous injections, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Phosphoinositide 3-Kinase (PI3K) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on phosphoinositide 3-kinase (pi3k) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for phosphoinositide 3-kinase (pi3k) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The phosphoinositide 3-kinase (pi3k) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Characteristics

3. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Trends And Strategies

4. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Growth Analysis And Strategic Analysis Framework

6. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmentation

7. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

9. China Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

10. India Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

11. Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

12. Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

13. Indonesia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

14. South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

15. Western Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

16. UK Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

17. Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

18. France Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

19. Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

20. Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

21. Eastern Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

22. Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

23. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

24. USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

25. Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

26. South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

27. Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

28. Middle East Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

29. Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

30. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Competitive Landscape And Company Profiles

31. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Other Major And Innovative Companies

32. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

34. Recent Developments In The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

35. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기